Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs

Respiratory Medicine CME

Volumn 3, Issue 3, 2010, Pages 125-131

  Haughney, John ^a   Price, David ^a   Barnes, Neil C ^b   Virchow, J Christian ^c   Roche, Nicolas ^d   Chrystyn, Henry ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d HÔTEL DIEU   (France)

^e UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Asthma control; Inhaler device; Inhaler technique; Primary care; Tool

Indexed keywords

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; HUMAN; INHALATION; INHALER; METERED DOSE INHALER; PARTICLE SIZE; POWDER INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 78549261378     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2010.10.004     Document Type: Article

References (60)

1. British Thoracic Society, Scottish Intercollegiate Guidelines Network British guideline on the management of asthma May 2008, revised June 2009. http://www.sign.ac.uk/guidelines/fulltext/101/index.html.
2. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention 2009, [Updated 2009]. http://www.ginasthma.org.
3. Sestini P., Cappiello V., Aliani M., et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med 2006, 19:127-136.
4. Haughney J., Price D., Kaplan A., et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008, 102:1681-1693.
5. Horne R., Price D., Cleland J., et al. Can asthma control be improved by understanding the patient's perspective?. BMC Pulm Med 2007, 7:8.
6. Brocklebank D., Ram F., Wright J., et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001, 5:1-149.
7. Brocklebank D., Wright J., Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001, 323:896-900.
8. Dolovich M.B., Ahrens R.C., Hess D.R., et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005, 127:335-371.
9. Cochrane M.G., Bala M.V., Downs K.E., Mauskopf J., Ben-Joseph R.H. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000, 117:542-550.
10. Lavorini F., Magnan A., Dubus J.C., et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008, 102:593-604.
11. Molimard M., Raherison C., Lignot S., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: An observational study in 3811 patients in primary care. J Aerosol Med 2003, 16:249-254.
12. Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med 2000, 94:496-500.
13. Schulte M., Osseiran K., Betz R., et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008, 21:321-328.
14. Hardwell A., Barber V., Hargadon T., Levy M. Technique training does not improve the ability of most patients to use pressurised Metered Dose Inhalers (pMDI). Prim Care Respir J 2009, 18:A1. Abstract.
15. Newman S.P., Weisz A.W., Talaee N., Clarke S.W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991, 46:712-716.
16. Lahdensuo A., Muittari A. Bronchodilator effects of a fenoterol metered dose inhaler and fenoterol powder in asthmatics with poor inhaler technique. Eur J Respir Dis 1986, 68:332-335.
17. Lindgren S., Bake B., Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis 1987, 70:93-98.
18. Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002, 19:246-251.
19. Khassawneh B.Y., Al-Ali M.K., Alzoubi K.H., et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care 2008, 53:324-328.
20. van der Palen J., Klein J.J., van Herwaarden C.L., Zielhuis G.A., Seydel E.R. Multiple inhalers confuse asthma patients. Eur Respir J 1999, 14:1034-1037.
21. Thomas M., Price D., Chrystyn H., Lloyd A., Williams A.E., von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009, 9:1.
22. Kemp L, Barnes N, Haughney J, Sims E, von Ziegenweidt J, Price D. The effectiveness of different inhaler types used in the " real-life" management of asthma (GPRD-REALITY). AAAAI Annual Meeting; 2009 13-17 March; Washington DC. Abstract.
23. Kemp L., Price D., Sims E., Dorinsky P., von Ziegenweidt J. 'Real-Life' Effectiveness of Qvar, Beclomethasone and Fluticasone. J Allergy Clin Immunol 2009, 123:6. Abstract.
24. Price D., Thomas M., Mitchell G., Niziol C., Featherstone R. Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respir Med 2003, 97:12-19.
25. Leach C.L., Davidson P.J., Hasselquist B.E., Boudreau R.J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002, 122:510-516.
26. Carstairs J.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985, 132:541-547.
27. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990, 141:1559-1568.
28. Jeffery P.K. Structural, immunologic, and neural elements of the normal human airway wall. Asthma and rhinitis 1995, 80-106. Blackwell Scientific Publications, Oxford. W. Busse, S.T. Holgate (Eds.).
29. Hamid Q., Song Y., Kotsimbos T.C., et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997, 100:44-51.
30. Tulic M.K., Hamid Q. New insights into the pathophysiology of the small airways in asthma. Clin Chest Med 2006, 27:41-52.
31. Chrystyn H. Anatomy and physiology in delivery: can we define our targets?. Allergy 1999, 54(Suppl. 49):82-87.
32. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172:1497-1504.
33. Al-Showair R.A., Pearson S.B., Chrystyn H. The potential of a 2Tone Trainer to help patients use their metered-dose inhalers. Chest 2007, 131:1776-1782.
34. Juniper E.F., Price D.B., Stampone P.A., Creemers J.P., Mol S.J., Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002, 121:1824-1832.
35. Martin R.J. Exploring the distal lung: new direction in asthma. Isr Med Assoc J 2008, 10:846-849.
36. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998, 12:1346-1353.
37. Busse W.W., Brazinsky S., Jacobson K., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999, 104:1215-1222.
38. Self T.H., Pinner N.A., Sowell R.S., Headley A.S. Does it really matter what volume to exhale before using asthma inhalation devices?. J Asthma 2009, 46:212-216.
39. Newman S.P., Pavia D., Garland N., Clarke S.W. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl 1982, 119:57-65.
40. Pauwels R., Newman S., Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997, 10:2127-2138.
41. Tomlinson H.S., Corlett S.A., Allen M.B., Chrystyn H. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharmacol 2005, 60:605-610.
42. Hesselink A.E., Penninx B.W., Wijnhoven H.A., Kriegsman D.M., van Eijk J.T. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care 2001, 19:255-260.
43. Nimmo C.J., Chen D.N., Martinusen S.M., Ustad T.L., Ostrow D.N. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother 1993, 27:922-927.
44. Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 1993, 6:99-110.
45. Chrystyn H., Price D. What you need to know about inhalers and how to use them. Prescriber 2009, 20(12):47-52.
46. Broeders M.E., Molema J., Vermue N.A., Folgering H.T. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J 2001, 18:780-783.
47. Weuthen T., Roeder S., Brand P., Mullinger B., Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med 2002, 15:297-303.
48. Palander A., Mattila T., Karhu M., Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler(R), Inspiryl Turbuhaler(R) and Ventoline Diskus(R). Clin Drug Investig 2000, 20:25-33.
49. Borgstrom L., Bondesson E., Moren F., Trofast E., Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994, 7:69-73.
50. Newman S.P., Morén F., Trofast E., Talaee N., Clarke S.W. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 1991, 74:209-213.
51. Bisgaard H., Klug B., Sumby B.S., Burnell P.K. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998, 11:1111-1115.
52. Broeders M.E., Molema J., Burnell P.K., Folgering H.T. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison. J Aerosol Med 2005, 18:74-82.
53. Tarsin W.Y., Pearson S.B., Assi K.H., Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm 2006, 316:131-137.
54. Diamond S.A., Chapman K.R. The impact of a nationally coordinated pharmacy-based asthma education intervention. Can Respir J 2001, 8:261-265.
55. Janson S.L., McGrath K.W., Covington J.K., Cheng S.C., Boushey H.A. Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol 2009, 123:840-846.
56. Basheti I.A., Armour C.L., Bosnic-Anticevich S.Z., Reddel H.K. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns 2008, 72:26-33.
57. Newman S.P., Talaee N., Clarke S.W. Salbutamol aerosol delivery in man with the Rondo-Spacer. Acta Ther 1991, 17:49-50.
58. Mazhar S.H., Chrystyn H. Salbutamol relative lung and systemic bioavailability of large and small spacers. J Pharm Pharmacol 2008, 60:1609-1613.
59. Ronmark E., Jogi R., Lindqvist A., et al. Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler. J Asthma 2005, 42:173-178.
60. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003, 97:181-187.